Clinical trials
Infliximab clinical trials
Below are recruiting infliximab clinical trials, each written for real people, not researchers. We’re tracking 36 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07470502Recruiting
Study of infliximab for children and teens with IBD
This trial is looking at children and teenagers with Crohn's disease or ulcerative colitis who are starting a biologic medicine called infliximab. It aims to learn more about how this treatment works in young patients.
Florence, ItalyAges 3–18 - NCT07385131Recruiting
Steroid before infliximab for inflammatory bowel disease
This study tests whether giving a steroid (dexamethasone) before an infliximab infusion can prevent allergic reactions in people with moderate-to-severe Crohn's disease or ulcerative colitis. If you qualify, you will receive either the steroid or a placebo before your infliximab treatment.
Hangzhou, ZhejiangAges 14–80 - NCT07237516Recruiting
Study of Zymfentra for people with Crohn's or colitis
This study follows adults with inflammatory bowel disease who are starting or switching to Zymfentra. Researchers will track your health over the next year to see how the medicine works in real life.
New Haven, ConnecticutAges 18 years+ - NCT07138898RecruitingPhase 2
Managing immune medications for shoulder replacement in rheumatology patients
This trial tests two ways of managing your immunosuppressant medication around the time of shoulder replacement surgery. The goal is to see if one approach leads to fewer infections while still controlling your rheumatic disease.
New York, New YorkAges 18 years+ - NCT07123207Recruiting
Probiotic with infliximab for Crohn's disease
This study is testing whether adding a probiotic (Bacillus subtilis) to standard infliximab treatment can improve outcomes for people with active Crohn's disease. It aims to see if the probiotic helps the medication work better.
Changsha, HunanAges 18–75 - NCT06995170Recruiting
Polyamines and IBD progression study
This study looks at how certain natural chemicals called polyamines relate to the activity of inflammatory bowel disease (IBD). It aims to understand if these chemicals can help predict disease progression.
Xi'an, ShaanxiAges 18–65 - NCT05928039RecruitingPhase 4
Choosing the best first biologic for Crohn’s in the ileum
This Phase 4 trial tests which type of biologic medicine works best as the first treatment for people with moderate-to-severe Crohn’s that mainly affects the ileum. It may help you and your care team choose a more effective first option, based on which strategy leads to better control of symptoms and intestinal inflammation.
Calgary, AlbertaAges 18 years+ - NCT06941376RecruitingPhase 2
Predicting disease course for better relapsing polychondritis care
This trial tests a new approach to treating relapsing polychondritis, a rare autoimmune condition that causes inflammation in cartilage like the ears, nose, and airways. It aims to see if a more tailored treatment can help control symptoms while reducing prednisone use.
Philadelphia, PennsylvaniaAges 18 years+ - NCT05823532RecruitingPhase 4
Anti-inflammatory treatment test in people with schizophrenia
This Phase 4 study tests how an anti-inflammatory approach affects people with schizophrenia or schizoaffective disorder who also have signs of body inflammation. It may help by targeting inflammation that could be linked to symptoms for some people.
Atlanta, GeorgiaAges 18–55 - NCT04646187Enrolling by invitationPhase 4
Lowering biologic doses for Crohn’s and ulcerative colitis
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
GhentAges 12–25 - NCT03819296RecruitingPhase 1
Fecal transplant to treat cancer immunotherapy bowel side effects
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
Houston, TexasAges 18 years+ - NCT03414502RecruitingPhase 3
Predictors of Response to DMARDs in Rheumatoid Arthritis
This trial studies rheumatoid arthritis (RA) patients starting or adjusting DMARD medicines and looks for signs that predict who responds best. It may help doctors choose more effective treatment sooner.
Omaha, NebraskaAges 19 years+
Hear when a new Infliximab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for infliximab?
- Yes. Clin2 currently lists 36 recruiting infliximab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a infliximab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a infliximab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.